CDK4 and breast cancer: There are attempts to combine CDK4/6 inhibitors with MEK inhibitors (for RAS-driven cancers) or PI3K inhibitors (for breast cancer), but to our knowledge this study is the first to propose the use of E2F/STAT3 inhibitor combination for GBM treatment [46].